SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-055666
Filing Date
2020-05-01
Accepted
2020-05-01 17:17:56
Documents
1
Period of Report
2020-04-29
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2015112-2_8k.htm 8-K 17795
  Complete submission text file 0001104659-20-055666.txt   19016
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 20841872
SIC: 2834 Pharmaceutical Preparations